Jiangsu Aidea Pharmaceutical to Join Specialised Earnings Briefing for Innovative Drug Firms on STAR Market

Deep News

Sep 07

Jiangsu Aidea Pharmaceutical Group Co., Ltd. (688488) has disclosed its intention to participate in a collective earnings presentation tailored for the innovative drug sector on the STAR Market, scheduled for the latter half of 2026.

According to an official announcement released on September 7, the company is set to join the event on September 16, 2026, from 3:00 PM to 5:00 PM. The session, organised by the Shanghai Stock Exchange, will serve as a platform for the semi-annual results review of innovative drug companies listed on the board.

This engagement underscores the company's commitment to transparent communication with investors and market participants, offering a comprehensive overview of its financial performance and strategic advancements during the reporting period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1106718626"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106718626\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106718626?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-07 19:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106718626","market":"us","top_or_hot":-1,"title":"Jiangsu Aidea Pharmaceutical to Join Specialised Earnings Briefing for Innovative Drug Firms on STAR Market","media":"Deep News","content":"<p><b>Jiangsu Aidea Pharmaceutical Group Co., Ltd.</b> (688488) has disclosed its intention to participate in a collective earnings presentation tailored for the innovative drug sector on the STAR Market, scheduled for the latter half of 2026.<br><br>According to an official announcement released on September 7, the company is set to join the event on September 16, 2026, from 3:00 PM to 5:00 PM. The session, organised by the Shanghai Stock Exchange, will serve as a platform for the semi-annual results review of innovative drug companies listed on the board.<br><br>This engagement underscores the company's commitment to transparent communication with investors and market participants, offering a comprehensive overview of its financial performance and strategic advancements during the reporting period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangsu Aidea Pharmaceutical to Join Specialised Earnings Briefing for Innovative Drug Firms on STAR Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangsu Aidea Pharmaceutical to Join Specialised Earnings Briefing for Innovative Drug Firms on STAR Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-09-07 19:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Jiangsu Aidea Pharmaceutical Group Co., Ltd.</b> (688488) has disclosed its intention to participate in a collective earnings presentation tailored for the innovative drug sector on the STAR Market, scheduled for the latter half of 2026.<br><br>According to an official announcement released on September 7, the company is set to join the event on September 16, 2026, from 3:00 PM to 5:00 PM. The session, organised by the Shanghai Stock Exchange, will serve as a platform for the semi-annual results review of innovative drug companies listed on the board.<br><br>This engagement underscores the company's commitment to transparent communication with investors and market participants, offering a comprehensive overview of its financial performance and strategic advancements during the reporting period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06978","symbol_name":"永泰生物-B","start_time":0,"source_url":"","article_id":"1106718626","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106718626","pubTimestamp":1788781895,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Jiangsu Aidea Pharmaceutical Group Co., Ltd. (688488) has disclosed its intention to participate in a collective earnings presentation tailored for the innovative drug sector on the STAR Market,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","688488":"艾迪药业","06978":"永泰生物-B","BK1161":"生物科技","KSTR":"中国科技半导体科创50指数ETF-KraneShares","BK1574":"生物医药B类股","BK0262":"其他制造","MEDX":"HORIZON KINETICS MEDICAL ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","LNGR":"Global X Longevity Thematic ETF"},"translate_title":"江苏爱德制药将参加科创板创新药企专项收益说明会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"688488":1,"06978":1,"LNGR":1,"KSTR":1,"MEDX":1,"IBBQ":1},"content_text":"Jiangsu Aidea Pharmaceutical Group Co., Ltd. (688488) has disclosed its intention to participate in a collective earnings presentation tailored for the innovative drug sector on the STAR Market, scheduled for the latter half of 2026.According to an official announcement released on September 7, the company is set to join the event on September 16, 2026, from 3:00 PM to 5:00 PM. The session, organised by the Shanghai Stock Exchange, will serve as a platform for the semi-annual results review of innovative drug companies listed on the board.This engagement underscores the company's commitment to transparent communication with investors and market participants, offering a comprehensive overview of its financial performance and strategic advancements during the reporting period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}